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Dear Professor Siepmann,
thank you very much for sending me the Reviewers’ comments on the manuscript “Nanoparticle 
drug delivery systems for inner ear therapy: an overview” (JDDST_2017_23) by Valente, Astolfi 
and coworkers.
One of the Reviewers mentioned that he/she did not find the Figure captions. Indeed, we had some 
problems in manuscript uploading: we checked on the journal site and could not find the file of 
Figure captions. We therefore enclose the missing Figure captions file for you and for the Reviewer.
Here enclosed you will find the detailed answers to the Reviewers. We hope that now our 
manuscript is suitable for publication on JDDST.
Kind regards,
Laura Astolfi, PhD
-----------------
Reviewer 1
The review presented by Valente et al « Nanoparticle drug delivery systems for inner ear therapy: 
an overview” is well-written and interesting.
I have the following minor comments/suggestions regarding the manuscript.
1. Lines 43-44 “The NP with size between 10 and 100 nm are useful for application in biology and 
medicine for innovative DD systems”. This range is a little bite too restrictive. The range 10 to 200 
nm is commonly used.
We thank the Reviewer for his/her comment and corrected the sentence according to the suggestion.
2. Line 53, please introduce the references of the reviews
According to the Reviewer’s suggestion, we introduced the references in the sentence.
3. Paragraph 2. Ear barrier
Drugs can also enter the inner ear via the oval window, another semi-permeable membrane located 
in the middle ear. It is important to mention in the paper the oval window as another route of 
penetration.
As suggested by the Reviewer, we mentioned the oval window together with the other inner ear 
barriers.
4. Lines 190 to 191 “Recently, the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) approved PLGA for parenteral administration (48)”. Please remove 
recently because PLGA microspheres and PLGA implants for the treatment of prostate cancer were 
marketed at the end of the eighties.
We deleted “recently” according to the Reviewer’s suggestion.
5. Paragraph 5. Key aspects for nanoparticles-based delivery in the inner ear
Lines 279 to 282. Supermagnetic iron oxide NPs (SPIONs) particles are not biodegradable. Please, 
add a comment on the long persistence of these particles in the inner ear and their potential toxicity 
due to their accumulation in this compartment.
We changed the sentence according to the Reviewer’s suggestion.
Lines 298 to 300 “The incorporation of loaded NP into hydrogels could increase their residence 
time in the middle ear, thus enhancing drug release in the perilymph». Please, add the reference El 
Kechai et al., “Hyaluronic acid liposomal gel sustains delivery of a corticoid to the inner ear, 
Journal of Controlled release, 2016, 226, 248-257”. This paper presents in vivo results on pegylated 
liposomes dispersed in hyaluronic hydrogel following injection in the middle ear. This recent paper 
completes examples on liposomes. 
- A prolonged residence time at the site of injection as well as in the round window were achieved 
without any negative effect on the hearing thresholds of the animals.
- The presence of liposomes in the formulation resulted in sustained release of the drug in the 
perilymph for 30 days and promoted the conversion of the prodrug loaded within the liposomes 
(dexamethasone phosphate) into its active form (dexamethasone).
- A small amount of intact liposomes was visualized in the perilymph, whereas the main proportion 
of liposomes seemed to be trapped in the round window resulting in a reservoir effect.
We thank the Reviewer for his/her comment and added the reference as suggested.
6. The quality of the figure entitled “Inner ear nanoparticles delivery” is not good. It is difficult to 
read the legend. 
We thank the Reviewer for his/her comment and improved the quality of the figure legends.
Reviewer 2
The manuscript focuses on recent findings and applications of different nanoparticle-based systems 
locally administered in the inner ear. This review is extensive and interesting, thus is worth be 
publication. There are several issues to be addressed:
It might be worthwhile to at least briefly review the disadvantage of local delivery to the inner ear 
in the first paragraph of “Introduction”.
We modified the sentence as suggested by the Reviewer.
The hierarchy of the manuscript should be reconstructed to be quite clearer, i.e. PLGA NPs don’t 
belong to the polymersomes and should be separated from “4.3. Polymersomes”.
We agree with the Reviewer that PLGA NPs are not polymersomes sensu stricto, therefore we 
corrected the title of the paragraph as “4.3 Polymersomes and copolymers” and specified their 
classification as copolymers in the text of the paragraph.
Keywords: “intratympanic” should be “intratympanic administration”.
We corrected the keyword according to the Reviewer’s suggestion
Reviewer 3
The review submitted by Filippo Valente et al. deals with different nanoparticles (NPs) used to 
administer drugs to the inner ear for the prevention of hearing loss.
After a short introduction into inner ear physiology, the different administration routes have been 
discussed. Since a minimally invasive technique seems to be promising, the review is focused on 
intratympanic administration of NPs. Subsequently, seven types of NPs are discussed giving 
examples from recent findings. Finally, a discussion about key aspects of inner ear drug delivery 
with NPs is presented.
The article gives a good overview on recent findings providing an interesting insight into new 
research. Also, the article is within the scope of the journal’s topics and written according to the 
journal’s standards pointed out in the guidelines for submission.
Minor remarks:
I did not find the legends of the figures. Please add them in the final version. Since the legend is 
missing, I cannot give comments on the figures. 
We thank the Reviewer for his/her remark. We checked on the journal site and could not find the 
file containing the figure captions, probably because of problems in uploading manuscript files. We 
therefore enclose a copy of the file containing the figure captions, as reference for the Reviewer and 
for the Editor.
Page 2, line 29: “…administered in the inner ear.”: I would replace “inner” by “middle” ear or “to 
deliver drugs to the inner ear” because with intratympanic administration normally the drug is 
administered in the middle ear cavity.
We corrected the sentence according to the Reviewer’s suggestion.
Page 3, line 50: Could you precise what do you mean by “perilymph rheology” and why it is 
“facilitating the distribution”? 
Research from Stefan Plontke and Alec N. Salt indicate the opposite: distribution of a drug inside 
the cochlea is even hindered so that a large concentration gradient is observed when the drug is 
administered intratympanically.
The term “rheology” indicates the flow of the matter in the liquid state, thus it can be applied to 
perilymph. We accordingly modified the sentence on drug distribution in the perilymph.
Page 3, line 51: The term used frequently is “Noise Induced Hearing Loss” or only “Hearing Loss”.
We corrected the sentence according to the Reviewer’s suggestion.
Page 4, line 91: “…induced side effects are developed.” Delete “induced”. 
We deleted the word “induced” from the sentence.
Page 6, line 131: Change the term “middle ear barrier”. Before, you have written “blood inner ear 
barrier (BB)” (page 3, line 62) and in my opinion it might be confusing if you name the RWM 
“middle ear barrier”.
We corrected the sentence according to the Reviewer’s suggestion.
Page 8, line 191: “PLGA” is singular, if you want to use plural in the following paragraph replace 
by “PLGA nanoparticles” or something similar. Please consider this remark for the whole paragraph 
until page 9, line 207.
According to the Reviewer’s suggestion, we added “NP” (nanoparticles) where required.
Page 11, line 242: Please write out “FITC” at least once.
Following the Reviewer’s suggestion, we substituted “FITC” with “fluorescein isothiocyanate”
Please correct the references:
17, 70 – Author names
26 – Points after author names
65, 70 – abbreviation of the journal
We corrected all references according to the Reviewer’s suggestion
Answer to Reviewers 
Reviewer 1
The review presented by Valente et al « Nanoparticle drug delivery systems for inner ear therapy: 
an overview” is well-written and interesting.
I have the following minor comments/suggestions regarding the manuscript.
1. Lines 43-44 “The NP with size between 10 and 100 nm are useful for application in biology and 
medicine for innovative DD systems”. This range is a little bite too restrictive. The range 10 to 200 
nm is commonly used.
We thank the Reviewer for his/her comment and corrected the sentence according to the suggestion.
2. Line 53, please introduce the references of the reviews
According to the Reviewer’s suggestion, we introduced the references in the sentence.
3. Paragraph 2. Ear barrier
Drugs can also enter the inner ear via the oval window, another semi-permeable membrane located 
in the middle ear. It is important to mention in the paper the oval window as another route of 
penetration.
As suggested by the Reviewer, we mentioned the oval window together with the other inner ear 
barriers.
4. Lines 190 to 191 “Recently, the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) approved PLGA for parenteral administration (48)”. Please remove 
recently because PLGA microspheres and PLGA implants for the treatment of prostate cancer were 
marketed at the end of the eighties.
We deleted “recently” according to the Reviewer’s suggestion.
5. Paragraph 5. Key aspects for nanoparticles-based delivery in the inner ear
Lines 279 to 282. Supermagnetic iron oxide NPs (SPIONs) particles are not biodegradable. Please, 
add a comment on the long persistence of these particles in the inner ear and their potential toxicity 
due to their accumulation in this compartment.
We changed the sentence according to the Reviewer’s suggestion.
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liposomes dispersed in hyaluronic hydrogel following injection in the middle ear. This recent paper 
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- A prolonged residence time at the site of injection as well as in the round window were achieved 
without any negative effect on the hearing thresholds of the animals.
- The presence of liposomes in the formulation resulted in sustained release of the drug in the 
perilymph for 30 days and promoted the conversion of the prodrug loaded within the liposomes 
(dexamethasone phosphate) into its active form (dexamethasone).
- A small amount of intact liposomes was visualized in the perilymph, whereas the main proportion 
of liposomes seemed to be trapped in the round window resulting in a reservoir effect.
We thank the Reviewer for his/her comment and added the reference as suggested.
6. The quality of the figure entitled “Inner ear nanoparticles delivery” is not good. It is difficult to 
read the legend. 
We thank the Reviewer for his/her comment and improved the quality of the figure legends.
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It might be worthwhile to at least briefly review the disadvantage of local delivery to the inner ear 
in the first paragraph of “Introduction”.
We modified the sentence as suggested by the Reviewer.
The hierarchy of the manuscript should be reconstructed to be quite clearer, i.e. PLGA NPs don’t 
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missing, I cannot give comments on the figures. 
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222 Abstract
23 Local drug delivery based on nanoparticles (NP) represents a novel strategy to improve inner ear 
24 treatments. The intratympanic delivery of NP may be suitable to treat or prevent hearing loss 
25 originating from damage to hair cells and spiral ganglion neurons in the cochlea. Numerous 
26 experimental studies support in vitro and in vivo the biocompatibility of NP, their physical stability, 
27 target specificity, cell/tissue uptake and ability to internalize therapeutic agents. The topical use of 
28 NP helps to reduce the amount of drug required and avoid systemic side effects. This review 
29 focuses on recent findings and applications of different NP systems locally delivered to the inner 
30 ear. The perspectives for clinical application of NP in inner ear drug delivery are also discussed.
31
32 Keywords
33 Nanoparticles, inner ear, drug delivery, intratympanic administration, local administration
34 1. Introduction
35 The treatment of inner ear diseases through drug delivery (DD) faces numerous challenges (1), 
36 among which the limited blood flow to the inner ear (2), the presence of physical barriers acting as 
37 a selective filter for drug transportation to the inner ear from the circulatory system (3), the small 
38 size of the cochlea and its isolated location in the petrous bone. As a result, research in local drug 
39 applications and medications has recently attracted interest because it is a more effective and 
40 preferable treatment than the systemic one. Case studies involving steroids (4) and gentamicin 
41 treatment for Meniere’s disease (5) have been documented, but these approaches could be improved 
42 for clinical protocols by the development of controlled and targeted delivery systems.
43 Nanoparticles (NP) are a possible option to improve existing therapeutic strategies (6). The NP with 
44 size between 10 and 200 nm are useful for application in biology and medicine for innovative DD 
45 systems. NP-based strategy could be more efficient and reduce drug-associated side effects because 
346 of the ability to deliver the therapeutic agent to the target site. Moreover, the controlled release of 
47 compounds conjugated to NP results in a lower dose of drug required to achieve the therapeutic 
48 effects (1, 7).
49 The cochlea is a good model for studying the NP-based DD due to its isolated structure and the 
50 perilymph rheology. The intratympanic delivery of NP could be suitable to treat the hearing loss 
51 and prevent its progression when hair cells and spiral ganglion neurons are damaged (8).
52 Several works and reviews have been published in the past decade, focusing on NP type, pathology 
53 involved, delivery approach or a combination of these topics (1-4, 6-8). The goal of the present 
54 review is to provide an updated general overview of NP-based strategies and their advantages and 
55 disadvantages for local DD into the inner ear.
56
57 2. Ear barriers
58 The human inner ear consists of two main parts, the auditory system (the cochlea) and the vestibular 
59 system. The cochlea is a bony spiral canal, about 30 mm long and divided in three fluid-filled 
60 compartments: the scala tympani, the scala media and the scala vestibuli. The round window 
61 membrane (RWM), the blood inner ear barrier (BB) and the oval window are physical barriers that 
62 isolate the cochlea from the middle ear and from the circulatory system (Figure 1). The RWM is a 
63 three-layer semi-permeable membrane, composed of an outer epithelial cell layer, a middle 
64 connection layer and an inner connection layer facing the perilymph of the scala tympani (9). In 
65 humans, the variable thickness of RWM affects the response of patients to DD treatments. In animal 
66 models, its thickness is different among species but its composition is similar (10).
67 Both the RWM and the oval window membranes have been investigated for DD, as connections 
68 between the middle ear cavity and the cochlear perilymph. The DD strategies for the inner ear 
69 currently rely mostly on RWM (11). The passage of molecules across this membrane is not only 
470 influenced by thickness, but also by its morphological integrity, inflammation and weight, 
71 concentration, liposolubility and external charge of the therapeutic compound (12). The drugs 
72 deposited topically in the middle ear cavity are internalized by pinocytosis and transported to the 
73 perilymph through blood vessels or by diffusion. Thus the direct application of drugs in the 
74 proximity of RWM is a suitable approach for treatment of inner ear pathologies (13).
75 The BB is a major barrier in the stria vascularis separating the cochlear tissues from the circulatory 
76 system (14). Its role is to maintain the homeostasis of cochlear fluids and protect the inner ear 
77 integrity. Its main components are principally the endothelial capillaries whose cells are connected 
78 by tight junctions, which lay over a basement membrane. However numerous accessory cells have 
79 recently been observed in the complex structure of the barrier, such as perycites and perivascular 
80 resident macrophage-like (11). The BB has been described to act as a physical and biochemical 
81 barrier through an efflux pump, the P-glycoprotein 1 (P-gp) (15). The BB is therefore considered a 
82 rate-limiting barrier in the passage of therapeutic agents from the circulatory system to the inner ear. 
83 However, the current knowledge about drug transportation processes through BB is still limited 
84 (16).
85
86 3. Administration routes
87 The clinical protocols for inner ear therapies mostly rely on systemic and local DD routes. The 
88 systemic administration represents a classical route for DD, but in the inner ear only few drugs may 
89 reach the target site at therapeutic concentrations. If high doses of systemic drugs are employed, 
90 often side effects are developed (17, 18). Systemic applications of NP in inner ear have been 
91 recently investigated: poly(lactic-co-glycolic acid) NP conjugated with rhodamine B and applied 
92 systemically were detected in the liver, but not in the cochlea (19). The limited bioavailability of NP 
93 after systemic administration could be due to the rapid clearance from the circulation in liver and 
94 spleen (20).
595 Local administration appears more suitable for inner ear DD (19). This approach allows a quick 
96 distribution of the drug inside the cochlea, improving their delivery to the target site; it also requires 
97 lower drug doses, avoiding side effects (21) (Figure 2). Two main routes are presently used for this 
98 purpose, the intratympanic (IT) or the intracochlear administration, but the second one is rarely 
99 performed because it is highly invasive and limited to surgery cases (22). On the contrary, the IT 
100 injection is minimally invasive and relies on passive diffusion of the active molecules through 
101 RWM to access the inner ear. This review focuses on development of these methods for DD with 
102 minimal trauma for the cochlea. However, local delivery trials show a high variability in results 
103 (23) because of some key factors: 1) the drug clearance within the middle ear through the 
104 Eustachian tube; 2) the permeability of RWM; and 3) the residence time of the drug in contact with 
105 RWM (24). A method to reduce variability of results and increase the drug concentration in the 
106 perilymph could be to better control the residence time of the drug at close range with RWM, using 
107 specific delivery systems based on NP (25).
108
109 4. Nanoparticle-based systems
110 The NP (also called nanocarriers or nanovectors) are artificial compounds with size at the 
111 nanoscale, which aim to compensate for adverse drug properties such as low solubility, degradation 
112 and short half-life (26). The NP may also be adapted to target a specific tissue of the inner ear. 
113 However, when injected in the middle ear as a liquid suspension, NP will undergo clearance 
114 through the Eustachian tube (27), thus significantly reducing their residence time near RWM. The 
115 NP suitable for DD systems should therefore increase the residence time, together with the ability to 
116 cross RWM and their biocompatibility (Figure 3). A detailed description of physico-chemical 
117 characteristics of NP and their applications is reported.
118 4.1. Lipid Core NP
6119 Lipid Core NP (LCN) possess a lipid core matrix (usually triglycerides) with a surrounding shell of 
120 lecithin, polyethylene glycol or poloxamers as stabilizing agents. The LCN structure can be 
121 changed to include different drugs and control the kinetics of drug release (28). It has been shown to 
122 be stable up to six months in aerosol dispersion (29). These NPs did not induce toxicological effects 
123 in vivo in mice after systemic applications (12 mg/kg intravenously for five days) (30) and their cell 
124 uptake and cell viability was in vitro verified on fibroblasts by confocal scanner laser microscopy 
125 (31). In rat animal models LCN were able to cross RWM and reach inner ear targets after middle 
126 ear application in vivo, while not affecting hearing capacity (32). Their preferred pathway to diffuse 
127 inside the cells was also investigated: they followed a “nerve pathway”, diffusing from the 
128 perilymph in the scala tympani to the spiral ganglion, nerve fibres and later approaching the inner 
129 and the outer hair cells (33). Their variability in diffusion and ability to cross RWM depends on 
130 their lipid composition, size and external charge. The ability to cross the RWM has been shown to 
131 be size-dependent, because the percentage of particle diffusion was inversely proportional to their 
132 size (31). Surface charge may also affect the uptake and biodistribution of LNC. Some NP 
133 candidates based on glycerol mono-oleate were studied under different external charges: after an in 
134 vivo application to RWM, LCN expressing stronger positive charges were detected in the deeper 
135 turns of the cochlea (34). The LCN were also tested as a drug carrier, delivering dexamethasone in 
136 the inner ear through IT injection and comparing the results with a systemic application of the same 
137 LCN. The amount of dexamethasone detected in cochlear fluid after local LCN application was 
138 significantly higher compared to the systemic application, also increasing the half-life and the 
139 average residence time of the drug in the perilymph by 1.9 folds (35). All these results indicate a 
140 great potential for LCN for sustained drug release and targeting of inner ear tissues after local 
141 administration.
142
143 4.2. Liposomes
7144 Liposomes are artificial phospholipid bilayers, similar to those found in the cell membrane, but 
145 surrounding an aqueous core. They exhibit a wide size range (between 50 nm and 5 µm) and 
146 morphology, depending on the phospholipid used and the preparation method (36). Liposomes can 
147 encapsulate either hydrophobic molecules in the phospholipid bilayer or hydrophilic molecules in 
148 their aqueous core (37). The uptake of these NP in vitro or in vivo usually relies on the passive 
149 diffusion inside the cells, but their surface can be modified with polyethylene glycol, antibodies, 
150 peptides, carbohydrates, hyaluronic acid and folic acid (35). Such modified liposomes successfully 
151 targeted cells expressing tropomyosin receptor-B (TrkB) by using 18-mer peptides to promote 
152 cellular uptake (38). Liposomes labelled with fluorescent markers applied in vivo to a mouse model 
153 with a single IT injection were identified in all cochlear turns, with a concentration gradient 
154 decreasing from the base to the apex and, to a lesser extent, in the lateral wall and in the organ of 
155 Corti. No morphological or functional damages to the inner ear were detected 24 hours after the 
156 application (8). Disulfiram, a neurotoxic agent, was used as model payload for DD analysis: NP 
157 loaded with Disulfiram damaged the spiral ganglion 48 hours after application, with an associated 
158 threshold shift reaching 35 dB. No significant effects were observed with a similar application of a 
159 pure Disulfiram solution (8). To test the drug delivery efficiency of liposome nanocarriers, NP of 
160 different size (95, 130, 240 nm) encapsulating the contrast agent gadolinium-tetra-azacyclo-
161 dodecane-tetra-acetic acid (Gd-DOTA) were applied in the middle ear and analyzed with MRI: the 
162 results showed that the liposome carrier efficiency was inversely proportional to NP size (39, 40).
163 4.3. Polymersomes and copolymers
164 The polymersomes (also called multifunctional NP) are a wide class of amphiphilic copolymers, 
165 consisting of a self-assembled membrane of hydrophobic units, surrounding an aqueous core, and of 
166 a hydrophilic corona (41). Structurally they are similar to liposomes, with the advantages that the 
167 membrane thickness can be controlled by the molecular weight of the hydrophobic block of 
168 copolymer to achieve stronger, thicker and more stable membranes. The hydrophilic corona can be 
8169 modified to regulate the biodistribution of polymersomes and induce specific cellular uptake (42). 
170 Hydrophilic drugs can be loaded in the core, while hydrophobic ones in the membrane (43).
171 Different multifunctional polymersomes were studied for inner ear DD targeting specific tissue or 
172 conjugated with ferromagnetic materials. 
173 In a mouse model, poly(ethylene glycol)-b-poly (ε-caprolactone) NP (PEG-b-PCL) labeled with 
174 fluorescent markers were detected in the spiral ganglion, in the organ of Corti and in the lateral wall 
175 after 24 hours from RWM application in vivo (8). Tissue specificity was also investigated: PEG-b-
176 PCL were conjugated with a nerve growth factor derived peptide and tested ex-vivo on explanted 
177 mouse cochleae and in vitro on PC12 cells. No significant toxic effect was observed and a specific 
178 targeting to spiral ganglion neurons, Schwann cells and nerve fibres was achieved by conjugating 
179 the NP with tyrosin kinase and p75 neurotrophin receptors (44).
180 Poly(2-hydroxyethyl aspartamide) NP (PHEA) were observed to enter in vitro the immortalized 
181 mouse organ of Corti cell line (HEI-OC1) and the human middle ear cell line (HMEEC). When 
182 applied in vivo near the RWM in a mouse model, PHEA were also detected in the inner ear tissue 
183 (45). In order to improve NP uptake, PHEA were modified with oligoarginine peptide, a positively 
184 charged copolymer, and conjugated with fluorescent Nile red as a hydrophobic model drug (46). In 
185 these conditions the NP uptake in vitro on HEI-OC1 and HMEEC cells was significantly improved 
186 after 15 and 24 hours, compared to pure Nile red solution. Modified PHEA were detected after 24 
187 hours from application in the inner hair cells and supporting cells (47).
188 Poly(lactic-co-glycolic acid) (PLGA) NP are copolymers among the novel carrier developed for 
189 DD. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
190 approved PLGA NP for parenteral administration (47). PLGA NP are interesting because of their 
191 hydrophilicity, biocompatibility and easy derivatization by functional groups on the surface or 
192 inside the polymer. Their surface may be modified for target specificity by PEGylation, chitosan 
9193 absorption and binding of antibodies and oligopeptides (48), and different molecules (proteins, 
194 steroids, antibiotics and nucleic acids) have been successfully encapsulated and delivered by PLGA 
195 NP (49). Programmed degradation of the polymer may therefore yield quantitative delivery of 
196 drugs, plasmids or other bioactive molecules. The PLGA NP tested in the inner ear were first 
197 conjugated with rhodamine B, a red fluorescent dye, and applied via IT injection: they were 
198 identified in the scala tympani, showing that PLGA NP are able to cross RWM by diffusion and 
199 their clearance depends on the perilymph flow rate (19). A quantitative pharmacokinetic study 
200 recently showed that PLGA NP applied locally in vivo in Guinea pigs significantly improved the 
201 drug distribution within the inner ear (52). When PLGA NP were loaded with the fluorescent dye 
202 coumarin-6 and applied through IT injection, the concentration of the compound after 96 hours 
203 from treatment was 10.9-fold higher in the perilymph than when administered in pure solution. 
204 Similar results were obtained for other therapeutic payloads such as antioxidants and antiapoptotic 
205 drugs (50). Thus PLGA NP are an useful DD system for inner ear because of their high versatility 
206 in adaptation to drug properties and tissue targets (51).
207
208 4.5. Silica NP
209 Silica NP are modified colloidal silica particles (52) used to transfect in vitro plasmid DNA (53) but 
210 also as a DD system (54). A pilot study in mice tested the efficacy of diffusion of Cy3-labeled silica 
211 NP administered near the RWM: these NP were found inside the inner hair cells, the vestibular hair 
212 cells, the spiral ganglion neurons and the supporting cells, without any hearing impairment. Since 
213 the NP also reached the dorsal cochlear nucleus and the superior olivary complex, the authors 
214 suggested a retrograde axonal transport and concluded that silica NP could be applied for safe drug 
215 deliver in the auditory system (55).
216 4.6. Supermagnetic iron oxide NPs (SPIONs)
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217 Magnetic NP are synthetic Fe3O4 (magnetite) particles, with a core diameter around 15 nm, that can 
218 be widely applied for magnetic targeting of cells (56). Unlike large ferromagnetic materials, the 
219 smaller supermagnetic iron oxide NP (SPION) are characterized by the absence of residual 
220 magnetic interactions when the magnetic field is not active, thus they are more suitable for 
221 biomedical applications (57). The SPION derivatized to increase biocompatibility and cell 
222 interactions could be guided by an external magnetic field to a specific biological target, but they 
223 cannot encapsulate any drug (58). For in vivo applications, to prevent particle aggregation and 
224 favour dispersion SPION were coated by organic compounds (59). In inner ear drug delivery, 
225 SPION have been encapsulated in PLGA (60), silica (58) and dextran (61) and their 
226 biocompatibility was tested and verified in vitro and in vivo (59). The mobility of SPION induced 
227 by a magnetic field was also quantified and the results of flux density, gradients and NP properties 
228 were compared between in vitro and in vivo models (62). The magnetic force required for SPION to 
229 cross RWM in vivo in Guinea pigs was significantly lower than that of the in vitro RWM model 
230 (63). Another study in vivo in Guinea pigs revealed that the concentration of coated SPION inside 
231 the cochlea significantly increased (330% above control) when a magnetic field was active (64). 
232 Recently, SPION coated with PGLA NP were tested as drug carriers with dexamethasone-acetate 
233 (Dex-Ac) as a payload: the levels of Dex-Ac detected in the inner ear fluids after 1 hour from 
234 treatment were significantly higher compared with those in absence of a magnetic field (65). All 
235 these results support the application of SPION for inner ear drug delivery protocols.
236
237 4.7. Hyperbranched poly-L-lysine NP
238 Hyperbranched poly-L-lysine (HBPL) are high cationic charged dendrimers widely used for non-
239 viral gene transfer (67, 68). The HBPL were applied in vivo in Guinea pig inner ears without any 
240 sign of cell toxicity or permanent hearing loss (31): they were detected in the stria vascularis and 
241 hair cells (31). Nanoparticles based on HBPL and conjugated with fluorescein isothiocyanate were 
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242 tested ex-vivo on freshly frozen human temporal bones, placing them near the intact RWM: HBPL 
243 were detected in hair cells, nerve fibres and other cochlear tissues (66).
244
245 5. Key aspects for nanoparticle-based drug delivery in the inner ear 
246 There are several key parameters to consider for NP-based local DD in the inner ear: the RWM 
247 permeability; the NP cochlear targeting; their payload ability and the controlled drug release; their 
248 biocompatibility and their stability in cochlear fluids and tissues. All these aspects were evaluated 
249 with different NP systems in vitro, ex-vivo or in vivo in animal models. However, studies on their 
250 therapeutic efficacy are still in progress (26). 
251 The RWM is considered the main access to the inner ear after the administration in the middle ear 
252 (67). NP with different composition and size between 10 and 640 nm were able to cross RWM. The 
253 size and the surface charge are determinant factors that affect NP diffusion through RWM. The 
254 number of NP crossing from middle ear to inner ear was inversely proportional to lipid NP size (39) 
255 and in the cochlea the positively charged glycerol mono-oleate NP achieved a larger distribution 
256 than neutral or negatively charged ones (34). The process responsible for this passage was firstly 
257 described for lipid NPs as a paracellular pathway (33). Recent studies in rat RWM suggested that 
258 the passage of liposome NP may occur either via the paracellular pathway or by endocytotic 
259 mechanisms based on clathrin and caveolin (8). 
260 In most studies NP were loaded or labelled with a fluorescent dye (Rhodamine B, Carboxycyanine, 
261 Nile-red) or a contrast agent (gadolinium) for visualization of particles in cochlear cells or fluids by 
262 imaging techniques: however, the reported data mostly detected the presence of NP in inner ear 
263 tissues without a quantitative analysis. Liposome NP were detected in RWM until 11 days and in 
264 the cochlea until 6 days post-injection (67); lipid nanocapsules were detected in the cochlea until 7 
265 days post-injection (33). However, for treatment of sensorineural hearing loss, the cochlear target 
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266 cells are hair cells and spiral ganglion neurons: all populations are selectively reached by the 
267 functionalized NP tested (51). For example, the NP functionalized with nerve growth factor-derived 
268 peptides showed specificity for spiral ganglion neurons and nerve fibres (44).
269 The ability of NP to carry the drugs into the cochlea through the RWM was shown in vivo by 
270 several studies. Smaller supermagnetic iron oxide NP (SPION) coated with PGLA and conjugated 
271 with dexamethasone enabled the release of the drug in inner ear fluids, resulting in a higher 
272 concentration of dexamethasone in the perilymph compared to the pure drug diffusion (10% higher 
273 after 60 minutes, p<0.01) (65). The PLGA loaded with coumarin-6 enhanced up to 10.9 times the 
274 local bioavailability of the dye in the perilymph in comparison to pure drug solution (50). When the 
275 neutoxic agent disulfiram was loaded on liposomes and polymersomes, the number of spiral 
276 ganglion cells significantly decreased two days after administration (8). However, drug release by 
277 NP has not yet been examined by long-term studies.
278 Biocompatibility is one of the major concerns in NP clinical applications. Up to date no hearing 
279 impairment, loss of hair cells or histological damages were reported (31, 32, 45, 68), thus NP 
280 systems appear reasonably safe. However, SPION tend to aggregate when the magnetic field is 
281 removed and the long persistence of these nanoparticles on the inner ear may induce toxicity due to 
282 accumulation (8). The effects of LNC were evaluated 20 days post-injection and no toxicity was 
283 detected (67). Topic applications of liposomes in rats did not affect hearing, but a NP concentration-
284 dependent toxicity was observed in vitro in primary cochlear cell cultures (32). A possible 
285 explanation was that a NP overload occurred in these cells, resulting in cytoplasm condensation and 
286 cell function impairment (69). In most of these studies a single intratympanic administration was 
287 employed: recently, in order to improve liposome efficiency, a continuous NP release was obtained 
288 through a high-performance polymide tubing (HPPT) equipped with an ALZET© micro-pump 
289 (DURECT Corp, CA; USA). Liposomes loaded with gadolinium-tetra-azacyclo-dodecane-tetra-
290 acetic acid were visualized both in vitro by TEM and in vivo by MRI. In vitro, intact NP were free 
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291 to diffuse in the medium, and in vivo were detected in the cochlea without adverse effects within six 
292 days (67). Again, no long-term effects of exposure to NP after multiple applications in the inner ear 
293 have yet been evaluated.
294 The residence time of the drug within the middle ear cavity may be increased by NP, but this does 
295 not guarantee direct contact between the loaded NP and the RWM, because the RWM is the access 
296 point for the inner ear in the case of trans-tympanic administration. The NP also undergo middle ear 
297 clearance through the Eustachian tube (70). A possible strategy to bypass these limits could be to 
298 combine different DD systems together, for example using hydrogels. The incorporation of loaded 
299 NP into hydrogels could increase their residence time in the middle ear, thus enhancing drug release 
300 in the perilymph (26, 71).The hydrogel is applied near the RWM and releases the loaded NP in the 
301 perilymph along with its degradation. This approach has been recently reported: a poloxamer 407 
302 hydrogel combined with SPION was successfully applied on ex vivo models (human temporal 
303 bones and explanted mouse inner ear cultures) (72). More recently, a nanohydrogel based on 
304 chitosan polymer incorporating liposomes was tested in vitro and in vivo in the mouse model (73). 
305 The in vitro results showed that NP persisted without significant degradation for at least two weeks 
306 and were released in a controlled and continuous way by the nanohydrogel. The in vivo results 
307 showed that the NP were successfully released by the nanohydrogel across the RWM and were able 
308 to reach the perilymph and Organ of Corti cells (73).
309 Although NP research in local DD for inner ear therapy appears promising, there are still many 
310 difficulties to overcome, mostly related to the inner ear anatomy, to the complexity of the cochlea 
311 and its highly differentiated cell populations, as well as the possibility to cause hearing loss using 
312 microsurgical approaches. The in vivo analyses of perilymph samples represent a technical 
313 challenge (27), because of the small volume of inner ear fluids in animal models (the total volume 
314 of perilymph in a Guinea pig amounts to about 10 µl) (74), and the possible contamination of 
315 samples by cerebrospinal fluid (27). The pharmacokinetics of drugs in the inner ear is therefore still 
14
316 unclear and there are no reliable quantitative data about local bioavailability, drug distribution and 
317 RWM permeability (26). Only recently, a computer pharmacokinetic for inner ear fluids and drug 
318 distribution has been developed (75). The software (Cochlear Fluids Simulator V3.083) outlines a 
319 model based on inner ear anatomy in humans and rodents, pharmacokinetic and solute distribution 
320 parameters. This model has been used to simulate the distribution of therapeutic drugs and other 
321 compounds in the perilymph (24, 76). However, because of intraspecific variability of animal 
322 models in the volume of inner ear fluids and RWM thickness and conditions, it is difficult to 
323 compare the current studies using different DD systems and to draw quantitative conclusions about 
324 drug pharmacokinetics in the inner ear.
325
326 6. Conclusions and Future Perspectives
327 The NP-based systems show a high potential for inner ear delivery of various therapeutic agents. 
328 Their use could minimize the side effects of treatments, allow target specificity and provide a 
329 sustained release of drugs in inner ear fluids. The type of NP may be adapted to the drug to be 
330 carried and different formulations have been tested. The NP could also be combined with other 
331 nanomaterials, such as hydrogels, to improve the local application of drugs. However, several 
332 problems have yet to be solved and more in vivo studies are necessary to verify their bioavailability 
333 and effectiveness before a successful clinical application.
334
335
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222 Abstract
23 Local drug delivery based on nanoparticles (NP) represents a novel strategy to improve inner ear 
24 treatments. The intratympanic delivery of NP may be suitable to treat or prevent hearing loss 
25 originating from damage to hair cells and spiral ganglion neurons in the cochlea. Numerous 
26 experimental studies support in vitro and in vivo the biocompatibility of NP, their physical stability, 
27 target specificity, cell/tissue uptake and ability to internalize therapeutic agents. The topical use of 
28 NP helps to reduce the amount of drug required and avoid systemic side effects. This review 
29 focuses on recent findings and applications of different NP systems locally delivered to the inner 
30 ear. The perspectives for clinical application of NP in inner ear drug delivery are also discussed.
31
32 Keywords
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34 1. Introduction
35 The treatment of inner ear diseases through drug delivery (DD) faces numerous challenges (1), 
36 among which the limited blood flow to the inner ear (2), the presence of physical barriers acting as 
37 a selective filter for drug transportation to the inner ear from the circulatory system (3), the small 
38 size of the cochlea and its isolated location in the petrous bone. As a result, research in local drug 
39 applications and medications has recently attracted interest because it is a more effective and 
40 preferable treatment than the systemic one. Case studies involving steroids (4) and gentamicin 
41 treatment for Meniere’s disease (5) have been documented, but these approaches could be improved 
42 for clinical protocols by the development of controlled and targeted delivery systems.
43 Nanoparticles (NP) are a possible option to improve existing therapeutic strategies (6). The NP with 
44 size between 10 and 200 nm are useful for application in biology and medicine for innovative DD 
45 systems. NP-based strategy could be more efficient and reduce drug-associated side effects because 
346 of the ability to deliver the therapeutic agent to the target site. Moreover, the controlled release of 
47 compounds conjugated to NP results in a lower dose of drug required to achieve the therapeutic 
48 effects (1, 7).
49 The cochlea is a good model for studying the NP-based DD due to its isolated structure and the 
50 perilymph rheology. The intratympanic delivery of NP could be suitable to treat the hearing loss 
51 and prevent its progression when hair cells and spiral ganglion neurons are damaged (8).
52 Several works and reviews have been published in the past decade, focusing on NP type, pathology 
53 involved, delivery approach or a combination of these topics (1-4, 6-8). The goal of the present 
54 review is to provide an updated general overview of NP-based strategies and their advantages and 
55 disadvantages for local DD into the inner ear.
56
57 2. Ear barriers
58 The human inner ear consists of two main parts, the auditory system (the cochlea) and the vestibular 
59 system. The cochlea is a bony spiral canal, about 30 mm long and divided in three fluid-filled 
60 compartments: the scala tympani, the scala media and the scala vestibuli. The round window 
61 membrane (RWM), the blood inner ear barrier (BB) and the oval window are physical barriers that 
62 isolate the cochlea from the middle ear and from the circulatory system (Figure 1). The RWM is a 
63 three-layer semi-permeable membrane, composed of an outer epithelial cell layer, a middle 
64 connection layer and an inner connection layer facing the perilymph of the scala tympani (9). In 
65 humans, the variable thickness of RWM affects the response of patients to DD treatments. In animal 
66 models, its thickness is different among species but its composition is similar (10).
67 Both the RWM and the oval window membranes have been investigated for DD, as connections 
68 between the middle ear cavity and the cochlear perilymph. The DD strategies for the inner ear 
69 currently rely mostly on RWM (11). The passage of molecules across this membrane is not only 
470 influenced by thickness, but also by its morphological integrity, inflammation and weight, 
71 concentration, liposolubility and external charge of the therapeutic compound (12). The drugs 
72 deposited topically in the middle ear cavity are internalized by pinocytosis and transported to the 
73 perilymph through blood vessels or by diffusion. Thus the direct application of drugs in the 
74 proximity of RWM is a suitable approach for treatment of inner ear pathologies (13).
75 The BB is a major barrier in the stria vascularis separating the cochlear tissues from the circulatory 
76 system (14). Its role is to maintain the homeostasis of cochlear fluids and protect the inner ear 
77 integrity. Its main components are principally the endothelial capillaries whose cells are connected 
78 by tight junctions, which lay over a basement membrane. However numerous accessory cells have 
79 recently been observed in the complex structure of the barrier, such as perycites and perivascular 
80 resident macrophage-like (11). The BB has been described to act as a physical and biochemical 
81 barrier through an efflux pump, the P-glycoprotein 1 (P-gp) (15). The BB is therefore considered a 
82 rate-limiting barrier in the passage of therapeutic agents from the circulatory system to the inner ear. 
83 However, the current knowledge about drug transportation processes through BB is still limited 
84 (16).
85
86 3. Administration routes
87 The clinical protocols for inner ear therapies mostly rely on systemic and local DD routes. The 
88 systemic administration represents a classical route for DD, but in the inner ear only few drugs may 
89 reach the target site at therapeutic concentrations. If high doses of systemic drugs are employed, 
90 often side effects are developed (17, 18). Systemic applications of NP in inner ear have been 
91 recently investigated: poly(lactic-co-glycolic acid) NP conjugated with rhodamine B and applied 
92 systemically were detected in the liver, but not in the cochlea (19). The limited bioavailability of NP 
93 after systemic administration could be due to the rapid clearance from the circulation in liver and 
94 spleen (20).
595 Local administration appears more suitable for inner ear DD (19). This approach allows a quick 
96 distribution of the drug inside the cochlea, improving their delivery to the target site; it also requires 
97 lower drug doses, avoiding side effects (21) (Figure 2). Two main routes are presently used for this 
98 purpose, the intratympanic (IT) or the intracochlear administration, but the second one is rarely 
99 performed because it is highly invasive and limited to surgery cases (22). On the contrary, the IT 
100 injection is minimally invasive and relies on passive diffusion of the active molecules through 
101 RWM to access the inner ear. This review focuses on development of these methods for DD with 
102 minimal trauma for the cochlea. However, local delivery trials show a high variability in results 
103 (23) because of some key factors: 1) the drug clearance within the middle ear through the 
104 Eustachian tube; 2) the permeability of RWM; and 3) the residence time of the drug in contact with 
105 RWM (24). A method to reduce variability of results and increase the drug concentration in the 
106 perilymph could be to better control the residence time of the drug at close range with RWM, using 
107 specific delivery systems based on NP (25).
108
109 4. Nanoparticle-based systems
110 The NP (also called nanocarriers or nanovectors) are artificial compounds with size at the 
111 nanoscale, which aim to compensate for adverse drug properties such as low solubility, degradation 
112 and short half-life (26). The NP may also be adapted to target a specific tissue of the inner ear. 
113 However, when injected in the middle ear as a liquid suspension, NP will undergo clearance 
114 through the Eustachian tube (27), thus significantly reducing their residence time near RWM. The 
115 NP suitable for DD systems should therefore increase the residence time, together with the ability to 
116 cross RWM and their biocompatibility (Figure 3). A detailed description of physico-chemical 
117 characteristics of NP and their applications is reported.
118 4.1. Lipid Core NP
6119 Lipid Core NP (LCN) possess a lipid core matrix (usually triglycerides) with a surrounding shell of 
120 lecithin, polyethylene glycol or poloxamers as stabilizing agents. The LCN structure can be 
121 changed to include different drugs and control the kinetics of drug release (28). It has been shown to 
122 be stable up to six months in aerosol dispersion (29). These NPs did not induce toxicological effects 
123 in vivo in mice after systemic applications (12 mg/kg intravenously for five days) (30) and their cell 
124 uptake and cell viability was in vitro verified on fibroblasts by confocal scanner laser microscopy 
125 (31). In rat animal models LCN were able to cross RWM and reach inner ear targets after middle 
126 ear application in vivo, while not affecting hearing capacity (32). Their preferred pathway to diffuse 
127 inside the cells was also investigated: they followed a “nerve pathway”, diffusing from the 
128 perilymph in the scala tympani to the spiral ganglion, nerve fibres and later approaching the inner 
129 and the outer hair cells (33). Their variability in diffusion and ability to cross RWM depends on 
130 their lipid composition, size and external charge. The ability to cross the RWM has been shown to 
131 be size-dependent, because the percentage of particle diffusion was inversely proportional to their 
132 size (31). Surface charge may also affect the uptake and biodistribution of LNC. Some NP 
133 candidates based on glycerol mono-oleate were studied under different external charges: after an in 
134 vivo application to RWM, LCN expressing stronger positive charges were detected in the deeper 
135 turns of the cochlea (34). The LCN were also tested as a drug carrier, delivering dexamethasone in 
136 the inner ear through IT injection and comparing the results with a systemic application of the same 
137 LCN. The amount of dexamethasone detected in cochlear fluid after local LCN application was 
138 significantly higher compared to the systemic application, also increasing the half-life and the 
139 average residence time of the drug in the perilymph by 1.9 folds (35). All these results indicate a 
140 great potential for LCN for sustained drug release and targeting of inner ear tissues after local 
141 administration.
142
143 4.2. Liposomes
7144 Liposomes are artificial phospholipid bilayers, similar to those found in the cell membrane, but 
145 surrounding an aqueous core. They exhibit a wide size range (between 50 nm and 5 µm) and 
146 morphology, depending on the phospholipid used and the preparation method (36). Liposomes can 
147 encapsulate either hydrophobic molecules in the phospholipid bilayer or hydrophilic molecules in 
148 their aqueous core (37). The uptake of these NP in vitro or in vivo usually relies on the passive 
149 diffusion inside the cells, but their surface can be modified with polyethylene glycol, antibodies, 
150 peptides, carbohydrates, hyaluronic acid and folic acid (35). Such modified liposomes successfully 
151 targeted cells expressing tropomyosin receptor-B (TrkB) by using 18-mer peptides to promote 
152 cellular uptake (38). Liposomes labelled with fluorescent markers applied in vivo to a mouse model 
153 with a single IT injection were identified in all cochlear turns, with a concentration gradient 
154 decreasing from the base to the apex and, to a lesser extent, in the lateral wall and in the organ of 
155 Corti. No morphological or functional damages to the inner ear were detected 24 hours after the 
156 application (8). Disulfiram, a neurotoxic agent, was used as model payload for DD analysis: NP 
157 loaded with Disulfiram damaged the spiral ganglion 48 hours after application, with an associated 
158 threshold shift reaching 35 dB. No significant effects were observed with a similar application of a 
159 pure Disulfiram solution (8). To test the drug delivery efficiency of liposome nanocarriers, NP of 
160 different size (95, 130, 240 nm) encapsulating the contrast agent gadolinium-tetra-azacyclo-
161 dodecane-tetra-acetic acid (Gd-DOTA) were applied in the middle ear and analyzed with MRI: the 
162 results showed that the liposome carrier efficiency was inversely proportional to NP size (39, 40).
163 4.3. Polymersomes and copolymers
164 The polymersomes (also called multifunctional NP) are a wide class of amphiphilic copolymers, 
165 consisting of a self-assembled membrane of hydrophobic units, surrounding an aqueous core, and of 
166 a hydrophilic corona (41). Structurally they are similar to liposomes, with the advantages that the 
167 membrane thickness can be controlled by the molecular weight of the hydrophobic block of 
168 copolymer to achieve stronger, thicker and more stable membranes. The hydrophilic corona can be 
8169 modified to regulate the biodistribution of polymersomes and induce specific cellular uptake (42). 
170 Hydrophilic drugs can be loaded in the core, while hydrophobic ones in the membrane (43).
171 Different multifunctional polymersomes were studied for inner ear DD targeting specific tissue or 
172 conjugated with ferromagnetic materials. 
173 In a mouse model, poly(ethylene glycol)-b-poly (ε-caprolactone) NP (PEG-b-PCL) labeled with 
174 fluorescent markers were detected in the spiral ganglion, in the organ of Corti and in the lateral wall 
175 after 24 hours from RWM application in vivo (8). Tissue specificity was also investigated: PEG-b-
176 PCL were conjugated with a nerve growth factor derived peptide and tested ex-vivo on explanted 
177 mouse cochleae and in vitro on PC12 cells. No significant toxic effect was observed and a specific 
178 targeting to spiral ganglion neurons, Schwann cells and nerve fibres was achieved by conjugating 
179 the NP with tyrosin kinase and p75 neurotrophin receptors (44).
180 Poly(2-hydroxyethyl aspartamide) NP (PHEA) were observed to enter in vitro the immortalized 
181 mouse organ of Corti cell line (HEI-OC1) and the human middle ear cell line (HMEEC). When 
182 applied in vivo near the RWM in a mouse model, PHEA were also detected in the inner ear tissue 
183 (45). In order to improve NP uptake, PHEA were modified with oligoarginine peptide, a positively 
184 charged copolymer, and conjugated with fluorescent Nile red as a hydrophobic model drug (46). In 
185 these conditions the NP uptake in vitro on HEI-OC1 and HMEEC cells was significantly improved 
186 after 15 and 24 hours, compared to pure Nile red solution. Modified PHEA were detected after 24 
187 hours from application in the inner hair cells and supporting cells (47).
188 Poly(lactic-co-glycolic acid) (PLGA) NP are copolymers among the novel carrier developed for 
189 DD. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
190 approved PLGA NP for parenteral administration (47). PLGA NP are interesting because of their 
191 hydrophilicity, biocompatibility and easy derivatization by functional groups on the surface or 
192 inside the polymer. Their surface may be modified for target specificity by PEGylation, chitosan 
9193 absorption and binding of antibodies and oligopeptides (48), and different molecules (proteins, 
194 steroids, antibiotics and nucleic acids) have been successfully encapsulated and delivered by PLGA 
195 NP (49). Programmed degradation of the polymer may therefore yield quantitative delivery of 
196 drugs, plasmids or other bioactive molecules. The PLGA NP tested in the inner ear were first 
197 conjugated with rhodamine B, a red fluorescent dye, and applied via IT injection: they were 
198 identified in the scala tympani, showing that PLGA NP are able to cross RWM by diffusion and 
199 their clearance depends on the perilymph flow rate (19). A quantitative pharmacokinetic study 
200 recently showed that PLGA NP applied locally in vivo in Guinea pigs significantly improved the 
201 drug distribution within the inner ear (52). When PLGA NP were loaded with the fluorescent dye 
202 coumarin-6 and applied through IT injection, the concentration of the compound after 96 hours 
203 from treatment was 10.9-fold higher in the perilymph than when administered in pure solution. 
204 Similar results were obtained for other therapeutic payloads such as antioxidants and antiapoptotic 
205 drugs (50). Thus PLGA NP are an useful DD system for inner ear because of their high versatility 
206 in adaptation to drug properties and tissue targets (51).
207
208 4.5. Silica NP
209 Silica NP are modified colloidal silica particles (52) used to transfect in vitro plasmid DNA (53) but 
210 also as a DD system (54). A pilot study in mice tested the efficacy of diffusion of Cy3-labeled silica 
211 NP administered near the RWM: these NP were found inside the inner hair cells, the vestibular hair 
212 cells, the spiral ganglion neurons and the supporting cells, without any hearing impairment. Since 
213 the NP also reached the dorsal cochlear nucleus and the superior olivary complex, the authors 
214 suggested a retrograde axonal transport and concluded that silica NP could be applied for safe drug 
215 deliver in the auditory system (55).
216 4.6. Supermagnetic iron oxide NPs (SPIONs)
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217 Magnetic NP are synthetic Fe3O4 (magnetite) particles, with a core diameter around 15 nm, that can 
218 be widely applied for magnetic targeting of cells (56). Unlike large ferromagnetic materials, the 
219 smaller supermagnetic iron oxide NP (SPION) are characterized by the absence of residual 
220 magnetic interactions when the magnetic field is not active, thus they are more suitable for 
221 biomedical applications (57). The SPION derivatized to increase biocompatibility and cell 
222 interactions could be guided by an external magnetic field to a specific biological target, but they 
223 cannot encapsulate any drug (58). For in vivo applications, to prevent particle aggregation and 
224 favour dispersion SPION were coated by organic compounds (59). In inner ear drug delivery, 
225 SPION have been encapsulated in PLGA (60), silica (58) and dextran (61) and their 
226 biocompatibility was tested and verified in vitro and in vivo (59). The mobility of SPION induced 
227 by a magnetic field was also quantified and the results of flux density, gradients and NP properties 
228 were compared between in vitro and in vivo models (62). The magnetic force required for SPION to 
229 cross RWM in vivo in Guinea pigs was significantly lower than that of the in vitro RWM model 
230 (63). Another study in vivo in Guinea pigs revealed that the concentration of coated SPION inside 
231 the cochlea significantly increased (330% above control) when a magnetic field was active (64). 
232 Recently, SPION coated with PGLA NP were tested as drug carriers with dexamethasone-acetate 
233 (Dex-Ac) as a payload: the levels of Dex-Ac detected in the inner ear fluids after 1 hour from 
234 treatment were significantly higher compared with those in absence of a magnetic field (65). All 
235 these results support the application of SPION for inner ear drug delivery protocols.
236
237 4.7. Hyperbranched poly-L-lysine NP
238 Hyperbranched poly-L-lysine (HBPL) are high cationic charged dendrimers widely used for non-
239 viral gene transfer (67, 68). The HBPL were applied in vivo in Guinea pig inner ears without any 
240 sign of cell toxicity or permanent hearing loss (31): they were detected in the stria vascularis and 
241 hair cells (31). Nanoparticles based on HBPL and conjugated with fluorescein isothiocyanate were 
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242 tested ex-vivo on freshly frozen human temporal bones, placing them near the intact RWM: HBPL 
243 were detected in hair cells, nerve fibres and other cochlear tissues (66).
244
245 5. Key aspects for nanoparticle-based drug delivery in the inner ear 
246 There are several key parameters to consider for NP-based local DD in the inner ear: the RWM 
247 permeability; the NP cochlear targeting; their payload ability and the controlled drug release; their 
248 biocompatibility and their stability in cochlear fluids and tissues. All these aspects were evaluated 
249 with different NP systems in vitro, ex-vivo or in vivo in animal models. However, studies on their 
250 therapeutic efficacy are still in progress (26). 
251 The RWM is considered the main access to the inner ear after the administration in the middle ear 
252 (67). NP with different composition and size between 10 and 640 nm were able to cross RWM. The 
253 size and the surface charge are determinant factors that affect NP diffusion through RWM. The 
254 number of NP crossing from middle ear to inner ear was inversely proportional to lipid NP size (39) 
255 and in the cochlea the positively charged glycerol mono-oleate NP achieved a larger distribution 
256 than neutral or negatively charged ones (34). The process responsible for this passage was firstly 
257 described for lipid NPs as a paracellular pathway (33). Recent studies in rat RWM suggested that 
258 the passage of liposome NP may occur either via the paracellular pathway or by endocytotic 
259 mechanisms based on clathrin and caveolin (8). 
260 In most studies NP were loaded or labelled with a fluorescent dye (Rhodamine B, Carboxycyanine, 
261 Nile-red) or a contrast agent (gadolinium) for visualization of particles in cochlear cells or fluids by 
262 imaging techniques: however, the reported data mostly detected the presence of NP in inner ear 
263 tissues without a quantitative analysis. Liposome NP were detected in RWM until 11 days and in 
264 the cochlea until 6 days post-injection (67); lipid nanocapsules were detected in the cochlea until 7 
265 days post-injection (33). However, for treatment of sensorineural hearing loss, the cochlear target 
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266 cells are hair cells and spiral ganglion neurons: all populations are selectively reached by the 
267 functionalized NP tested (51). For example, the NP functionalized with nerve growth factor-derived 
268 peptides showed specificity for spiral ganglion neurons and nerve fibres (44).
269 The ability of NP to carry the drugs into the cochlea through the RWM was shown in vivo by 
270 several studies. Smaller supermagnetic iron oxide NP (SPION) coated with PGLA and conjugated 
271 with dexamethasone enabled the release of the drug in inner ear fluids, resulting in a higher 
272 concentration of dexamethasone in the perilymph compared to the pure drug diffusion (10% higher 
273 after 60 minutes, p<0.01) (65). The PLGA loaded with coumarin-6 enhanced up to 10.9 times the 
274 local bioavailability of the dye in the perilymph in comparison to pure drug solution (50). When the 
275 neutoxic agent disulfiram was loaded on liposomes and polymersomes, the number of spiral 
276 ganglion cells significantly decreased two days after administration (8). However, drug release by 
277 NP has not yet been examined by long-term studies.
278 Biocompatibility is one of the major concerns in NP clinical applications. Up to date no hearing 
279 impairment, loss of hair cells or histological damages were reported (31, 32, 45, 68), thus NP 
280 systems appear reasonably safe. However, SPION tend to aggregate when the magnetic field is 
281 removed and the long persistence of these nanoparticles on the inner ear may induce toxicity due to 
282 accumulation (8). The effects of LNC were evaluated 20 days post-injection and no toxicity was 
283 detected (67). Topic applications of liposomes in rats did not affect hearing, but a NP concentration-
284 dependent toxicity was observed in vitro in primary cochlear cell cultures (32). A possible 
285 explanation was that a NP overload occurred in these cells, resulting in cytoplasm condensation and 
286 cell function impairment (69). In most of these studies a single intratympanic administration was 
287 employed: recently, in order to improve liposome efficiency, a continuous NP release was obtained 
288 through a high-performance polymide tubing (HPPT) equipped with an ALZET© micro-pump 
289 (DURECT Corp, CA; USA). Liposomes loaded with gadolinium-tetra-azacyclo-dodecane-tetra-
290 acetic acid were visualized both in vitro by TEM and in vivo by MRI. In vitro, intact NP were free 
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291 to diffuse in the medium, and in vivo were detected in the cochlea without adverse effects within six 
292 days (67). Again, no long-term effects of exposure to NP after multiple applications in the inner ear 
293 have yet been evaluated.
294 The residence time of the drug within the middle ear cavity may be increased by NP, but this does 
295 not guarantee direct contact between the loaded NP and the RWM, because the RWM is the access 
296 point for the inner ear in the case of trans-tympanic administration. The NP also undergo middle ear 
297 clearance through the Eustachian tube (70). A possible strategy to bypass these limits could be to 
298 combine different DD systems together, for example using hydrogels. The incorporation of loaded 
299 NP into hydrogels could increase their residence time in the middle ear, thus enhancing drug release 
300 in the perilymph (26, 71).The hydrogel is applied near the RWM and releases the loaded NP in the 
301 perilymph along with its degradation. This approach has been recently reported: a poloxamer 407 
302 hydrogel combined with SPION was successfully applied on ex vivo models (human temporal 
303 bones and explanted mouse inner ear cultures) (72). More recently, a nanohydrogel based on 
304 chitosan polymer incorporating liposomes was tested in vitro and in vivo in the mouse model (73). 
305 The in vitro results showed that NP persisted without significant degradation for at least two weeks 
306 and were released in a controlled and continuous way by the nanohydrogel. The in vivo results 
307 showed that the NP were successfully released by the nanohydrogel across the RWM and were able 
308 to reach the perilymph and Organ of Corti cells (73).
309 Although NP research in local DD for inner ear therapy appears promising, there are still many 
310 difficulties to overcome, mostly related to the inner ear anatomy, to the complexity of the cochlea 
311 and its highly differentiated cell populations, as well as the possibility to cause hearing loss using 
312 microsurgical approaches. The in vivo analyses of perilymph samples represent a technical 
313 challenge (27), because of the small volume of inner ear fluids in animal models (the total volume 
314 of perilymph in a Guinea pig amounts to about 10 µl) (74), and the possible contamination of 
315 samples by cerebrospinal fluid (27). The pharmacokinetics of drugs in the inner ear is therefore still 
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316 unclear and there are no reliable quantitative data about local bioavailability, drug distribution and 
317 RWM permeability (26). Only recently, a computer pharmacokinetic for inner ear fluids and drug 
318 distribution has been developed (75). The software (Cochlear Fluids Simulator V3.083) outlines a 
319 model based on inner ear anatomy in humans and rodents, pharmacokinetic and solute distribution 
320 parameters. This model has been used to simulate the distribution of therapeutic drugs and other 
321 compounds in the perilymph (24, 76). However, because of intraspecific variability of animal 
322 models in the volume of inner ear fluids and RWM thickness and conditions, it is difficult to 
323 compare the current studies using different DD systems and to draw quantitative conclusions about 
324 drug pharmacokinetics in the inner ear.
325
326 6. Conclusions and Future Perspectives
327 The NP-based systems show a high potential for inner ear delivery of various therapeutic agents. 
328 Their use could minimize the side effects of treatments, allow target specificity and provide a 
329 sustained release of drugs in inner ear fluids. The type of NP may be adapted to the drug to be 
330 carried and different formulations have been tested. The NP could also be combined with other 
331 nanomaterials, such as hydrogels, to improve the local application of drugs. However, several 
332 problems have yet to be solved and more in vivo studies are necessary to verify their bioavailability 
333 and effectiveness before a successful clinical application.
334
335
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Figure Legends
Fig. 1. Scheme of the cochlea structure, highlighting the cochlear barriers, the round window and 
the stria vascularis.
Fig. 2. Scheme of nanoparticle administration routes. Arrow: intratympanic route; black arrowhead: 
intracochlear route by round window; white arrowhead: intracochlear route by cochleostomy.
Fig. 3. Structures of nanoparticles (NP) useful for drug delivery. LCN: lipid core NP; SPION: 
supermagnetic iron oxide NP; HBPL: hyperbranched poly-L-lysine NP; P: hydrophilic region; NP: 
hydrophobic region.



